Bioengine Capital Inc. - May 20, 2020 Form 4 Insider Report for WINDTREE THERAPEUTICS INC /DE/ (WINT)

Role
10%+ Owner
Signature
/s/ Lin, Jung-Chin
Stock symbol
WINT
Transactions as of
May 20, 2020
Transactions value $
-$1,582,544
Form type
4
Date filed
1/10/2022, 04:03 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction WINT Common Stock Other $0 -3.55M -75% $0.00 1.18M May 20, 2020 Direct F1, F2
transaction WINT Common Stock Purchase $400K +55.2K +4.66% $7.25 1.24M May 20, 2020 Direct F2
transaction WINT Common Stock Sale -$1.98M -1.24M -100% $1.60 0 Dec 30, 2021 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction WINT SERIES F WARRANTS Other $0 0 $0.00* 0 Jun 24, 2020 Common Stock 385K $3.68 Direct F4
transaction WINT SERIES G WARRANTS Other $0 -249K -50% $0.00 249K May 20, 2020 Common Stock 249K $12.15 Direct F5, F6
transaction WINT SERIES J WARRANTS Purchase $0 +55.2K $0.00 55.2K May 20, 2020 Common Stock 55.2K $7.98 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Bioengine Capital Inc. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The Reporting Person voluntarily discloses that, on May 20, 2020, the Issuer effected a 1-for-3 reverse stock split of its Common Stock (the "Reverse Stock Split"), which resulted in the Reporting Person's ownership of issued and outstanding Common Stock being reduced from 3,551,750 shares of Common Stock to 1,183,916 shares of Common Stock.
F2 The shares were directly held by the Reporting Person and indirectly held by Center Laboratories, Inc., which owns 58.6% of the Reporting Person.
F3 On December 30, 2021, the Reporting Person sold all its remaining shares of Common Stock to Center Laboratories, Inc., which owns 58.6% of the Reporting Person. As a result of the foregoing transaction, the Reporting Person now directly owns 0 shares of Common Stock.
F4 The Reporting Person voluntarily discloses that, on July 24, 2020, Series F Warrants had expired. As a result, the Reporting Person now directly owns 0 shares of Series F Warrants.
F5 The Reporting Person voluntarily discloses that, on May 20, 2020, in connection with the Reverse Stock Split, the Issuer effected a 1-for-3 reverse split of all of its issued and outstanding Series G Warrants, which resulted in the Reporting Person's ownership of Series G Warrants being reduced from 747,012 shares of Series G Warrants to 249,004 shares of Series G Warrants.
F6 The exercise of the Series G Warrants is subject to a beneficial ownership limitation of 9.99% and this limitation can only be changed with effect from the 61st day after a notice requesting such change is delivered to the Issuer.

Remarks:

This filing constitutes a Form 4 exit filing for the Reporting Person, as the Reporting Person is no longer subject to Section 16 of the Securities Exchange Act of 1934, as amended, as a result of the transactions reported herein.